Skip to main content
Psych Congress  

Satisfaction With Quality of Care and Medication Among Patients with Schizophrenia Treated With Atypical Long-Acting Injectable Antipsychotics in Community Behavioral Health Organizations

Authors  
Kruti Joshi, MPH
Lian Mao, PhD
David Biondi, DO
John Fastenau, RPh, MPH
Robert Millet, MD, DFAPA
Sponsor  
Janssen Scientific Affairs

Objective: To assess satisfaction with quality of care (QOC) and medication among patients with schizophrenia treated with either paliperidone palmitate (PP) or risperidone long-acting injectable (RLAI) in Community Behavioral Health Organizations (CBHO).

Methods: This descriptive analysis used the final dataset from REACH OUT, a concluded naturalistic prospective, observational study of 599 patients with schizophrenia treated with atypical long-acting atypical antipsychotics (LAI). Satisfaction with QOC received from CBHO sites was measured using a 4-point Likert scale. Medication satisfaction was measured with a validated single-item medication satisfaction questionnaire (MSQ). The change in satisfaction from enrollment to 1-year follow-up was assessed descriptively.

Results: PP (new=174; continuous=308) and RLAI (new=40; continuous=77) users who completed a 1-year follow-up period were analyzed. The patient characteristics and psychiatric histories appeared similar between both cohorts. Increased percentage of new (62.9% to 73.8%) and continuous users (74.4% to 76.1%) of PP, and new users of RLAI (55.6% to 61.9%) were "very-satisfied" with QOC from enrollment to 1-year. Meanwhile, there was indication of reduction in the "very satisfied" rating in the continuous users of RLAI. Patient satisfaction with current antipsychotic medication increased for new users of both PP (66.7% to 73.8%) and RLAI cohorts (59.4% to 65.0%). Meanwhile, patient satisfaction with current antipsychotic medication was maintained for continuous PP users (72.6% to 72.0%), and a decrease in satisfaction was reported for continuous RLAI users (74.3% to 66.0%).

Conclusions: These initial results demonstrate a potential long-term benefit from PP treatment. Further comparative analyses using propensity score matching are ongoing.

Back to Top